Wellspring is organized around the discovery and development of small molecule drugs that target signal transduction networks for the treatment of cancer and other diseases. Through partnerships with academic and industry experts, the firm is translating chemical and biological insights into novel, highly targeted drugs. The team has a proven track record, having previously played important roles in the discovery and development of clinical-stage compounds for the treatment of cancer and immune-mediated inflammatory disease at pharmaceutical company Intellikine. Since early 2013, firm has had close ties to Janssen Biotech (J&J). Parent company is Araxes Pharma with principals of the firm also having close ties Kura Oncology Inc (KURA.OQ).
